QQQ   359.48 (-1.39%)
AAPL   174.71 (-0.44%)
MSFT   320.73 (-0.01%)
META   297.28 (-0.80%)
GOOGL   130.93 (-2.10%)
AMZN   130.02 (-3.90%)
TSLA   257.12 (-2.08%)
NVDA   412.74 (-2.28%)
NIO   8.49 (-3.74%)
BABA   84.32 (-1.66%)
AMD   96.47 (-3.86%)
T   15.35 (-1.29%)
F   12.24 (-0.97%)
MU   68.37 (-1.88%)
CGC   0.78 (-10.34%)
GE   113.59 (-1.10%)
DIS   82.67 (+0.13%)
AMC   7.75 (-5.02%)
PFE   32.96 (-1.96%)
PYPL   58.92 (-3.19%)
NFLX   385.78 (-0.13%)
QQQ   359.48 (-1.39%)
AAPL   174.71 (-0.44%)
MSFT   320.73 (-0.01%)
META   297.28 (-0.80%)
GOOGL   130.93 (-2.10%)
AMZN   130.02 (-3.90%)
TSLA   257.12 (-2.08%)
NVDA   412.74 (-2.28%)
NIO   8.49 (-3.74%)
BABA   84.32 (-1.66%)
AMD   96.47 (-3.86%)
T   15.35 (-1.29%)
F   12.24 (-0.97%)
MU   68.37 (-1.88%)
CGC   0.78 (-10.34%)
GE   113.59 (-1.10%)
DIS   82.67 (+0.13%)
AMC   7.75 (-5.02%)
PFE   32.96 (-1.96%)
PYPL   58.92 (-3.19%)
NFLX   385.78 (-0.13%)
QQQ   359.48 (-1.39%)
AAPL   174.71 (-0.44%)
MSFT   320.73 (-0.01%)
META   297.28 (-0.80%)
GOOGL   130.93 (-2.10%)
AMZN   130.02 (-3.90%)
TSLA   257.12 (-2.08%)
NVDA   412.74 (-2.28%)
NIO   8.49 (-3.74%)
BABA   84.32 (-1.66%)
AMD   96.47 (-3.86%)
T   15.35 (-1.29%)
F   12.24 (-0.97%)
MU   68.37 (-1.88%)
CGC   0.78 (-10.34%)
GE   113.59 (-1.10%)
DIS   82.67 (+0.13%)
AMC   7.75 (-5.02%)
PFE   32.96 (-1.96%)
PYPL   58.92 (-3.19%)
NFLX   385.78 (-0.13%)
QQQ   359.48 (-1.39%)
AAPL   174.71 (-0.44%)
MSFT   320.73 (-0.01%)
META   297.28 (-0.80%)
GOOGL   130.93 (-2.10%)
AMZN   130.02 (-3.90%)
TSLA   257.12 (-2.08%)
NVDA   412.74 (-2.28%)
NIO   8.49 (-3.74%)
BABA   84.32 (-1.66%)
AMD   96.47 (-3.86%)
T   15.35 (-1.29%)
F   12.24 (-0.97%)
MU   68.37 (-1.88%)
CGC   0.78 (-10.34%)
GE   113.59 (-1.10%)
DIS   82.67 (+0.13%)
AMC   7.75 (-5.02%)
PFE   32.96 (-1.96%)
PYPL   58.92 (-3.19%)
NFLX   385.78 (-0.13%)
NASDAQ:NUVL

Nuvalent (NUVL) Stock Forecast, Price & News

$43.16
+0.54 (+1.27%)
(As of 02:55 PM ET)
Compare
Today's Range
$42.19
$43.48
50-Day Range
$41.11
$49.85
52-Week Range
$15.56
$50.58
Volume
304,116 shs
Average Volume
280,274 shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.60

Nuvalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
14.5% Upside
$48.60 Price Target
Short Interest
Bearish
10.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.60mentions of Nuvalent in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.12) to ($2.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

799th out of 961 stocks

Pharmaceutical Preparations Industry

377th out of 449 stocks


NUVL stock logo

About Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Price History

NUVL Stock News Headlines

Nuvalent (NUVL) Receives a Buy from Piper Sandler
Out Of This World Stock Alerts!
There Is This One Lithium Stock That Has Our Full Attention! Sign Up And Learn More!
Nuvalent's (NUVL) "Outperform" Rating Reaffirmed at Wedbush
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Expert Ratings for Nuvalent
Nuvalent: Q1 Earnings Insights
BMO Capital Keeps Their Buy Rating on Nuvalent (NUVL)
See More Headlines
Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

NUVL Company Calendar

Last Earnings
8/10/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NUVL
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.60
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+13.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-81,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.59 per share

Miscellaneous

Free Float
48,602,000
Market Cap
$2.44 billion
Optionable
Not Optionable
Beta
1.35
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. James R. Porter Ph.D. (Age 47)
    CEO, Pres & Director
    Comp: $998.02k
  • Prof. Matthew D. Shair Ph.D. (Age 54)
    Founder, Head of Scientific Advisory Board & Director
    Comp: $235k
  • Ms. Alex Balcom CPA (Age 38)
    M.B.A., CFO & Treasurer
    Comp: $654.22k
  • Dr. Christopher D. Turner M.D. (Age 54)
    Chief Medical Officer
    Comp: $714.26k
  • Dr. Benjamin Lane
    Sr. VP of Technical Operations
  • Ms. Deborah Ann Miller J.D. (Age 47)
    Ph.D., Chief Legal Officer & Sec.
  • Mr. Matthew Metivier
    VP of HR
  • Ms. Darlene Noci (Age 46)
    Chief Devel. Officer
  • Mr. Henry Pelish Ph.D.
    Sr. VP of Drug Discovery
  • Mr. John Soglia Ph.D.
    Sr. VP of Translational Devel.













NUVL Stock - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings
or view top-rated stocks.

What is Nuvalent's stock price forecast for 2023?

6 analysts have issued 12 month price targets for Nuvalent's stock. Their NUVL share price forecasts range from $42.00 to $56.00. On average, they expect the company's share price to reach $48.60 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price.
View analysts price targets for NUVL
or view top-rated stocks among Wall Street analysts.

How have NUVL shares performed in 2023?

Nuvalent's stock was trading at $29.78 at the beginning of 2023. Since then, NUVL stock has increased by 43.8% and is now trading at $42.82.
View the best growth stocks for 2023 here
.

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our NUVL earnings forecast
.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) announced its earnings results on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04.

What ETFs hold Nuvalent's stock?

ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS).

When did Nuvalent IPO?

(NUVL) raised $151 million in an IPO on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share.

What is Nuvalent's stock symbol?

Nuvalent trades on the NASDAQ under the ticker symbol "NUVL."

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.22%), Perceptive Advisors LLC (3.86%), Driehaus Capital Management LLC (2.54%), State Street Corp (2.06%), Commodore Capital LP (2.02%) and Geode Capital Management LLC (0.93%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends
.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvalent's stock price today?

One share of NUVL stock can currently be purchased for approximately $42.82.

How much money does Nuvalent make?

Nuvalent (NASDAQ:NUVL) has a market capitalization of $2.44 billion. The company earns $-81,850,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How can I contact Nuvalent?

The official website for the company is www.nuvalent.com. The company can be reached via phone at 857-357-7000 or via email at ir@nuvalent.com.

This page (NASDAQ:NUVL) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -